Investigator Financial Disclosure Revised Rule Limits Retrospective Reports
Executive Summary
Retrospective collection of financial information about clinical investigators' equity interests in publicly traded companies has been eliminated from FDA's "Financial Disclosure by Clinical Investigators" final rule.
You may also be interested in...
Financial Disclosure Applies To Firms Providing Drugs For Public Studies
Pharmaceutical companies that contribute drugs to publicly funded studies used to support marketing applications will be responsible for collecting investigator financial interest information, an updated financial disclosure guidance notes.
Voluntary Financial Disclosure Guidelines Being Considered By PhRMA
PhRMA is considering the development of voluntary guidelines on financial interest disclosure for researchers publishing study results as part of a strategy to improve the pharmaceutical industry's image in a climate in which questions have arisen about investigator-sponsor relationships.
Voluntary Financial Disclosure Guidelines Being Considered By PhRMA
PhRMA is considering the development of voluntary guidelines on financial interest disclosure for researchers publishing study results as part of a strategy to improve the pharmaceutical industry's image in a climate in which questions have arisen about investigator-sponsor relationships.